Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCESS Study: CCX168 in ESRD Patients with Atypical Hemolytic Uremic Syndrome
2014-004261-24Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avacopan in atypical hemolytic uremic syndrome (aHUS), hemolytic uremic syndrome (HUS) and end-stage kidney disease (ESKD), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Ex vivo thrombogenesis. Started Sep 2018; status: terminated.
02
Drugs
avacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)hemolytic uremic syndrome (HUS)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2014-004261-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004261-24.